
Request Appointment
12902 Usf Magnolia DrTampa, FL 33612
Overview of Dr. Al-Jumayli
Dr. Mohammed Al-Jumayli is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Al-Mustansiriyah College of Medicine and has been in practice 18 years. He is one of 184 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 30 publications and over 200 citings.
Education & Training
Capital Health Regional Medical CenterResidency, Internal Medicine, 2013 - 2016
University of Al-Mustansiriyah College of MedicineClass of 1999
Certifications & Licensure
FL State Medical License 2020 - 2026
KS State Medical License 2017 - 2020
NJ State Medical License 2014 - 2018
MA State Medical License 2015 - 2015
PA State Medical License 2015 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Geriatric Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- ASCO Annual Meeting Merit Awards, Conquer Cancer ASCO, Conquer Cancer foundation, 2020
Publications & Presentations
PubMed
- Early Supportive and Nutritional Care For Adults With Pancreatic Cancer: A Pilot Study.Yu Chen Lin, Kea Turner, Sahana Rajasekhara, Dae Won Kim, Tiago Biachi de Castria
Journal of Pain and Symptom Management. 2025-11-01 - Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab.Jamila Mammadova, Alicia Richards, Adriana Gonzalez-Torriente, Evan R Adler, Rachel J Cruz
Cardio-Oncology. 2025-05-10 - Feasibility trial of STRONG: A digital intervention to improve nutritional management for individuals with esophageal and gastroesophageal junction cancer.Yu Chen Lin, Jose M Pimiento, Jeanine Milano, Diane Riccardi, Nakesha Mckinnie
Contemporary Clinical Trials Communications. 2025-02-01
Journal Articles
- Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective StudyA. Saeed, H. Hildebrand, R. Park, M. Al-Jumayli, S. Abbasi, T. Melancon, A. Saeed, R. Al-Rajabi, A. Kasi, J. Baranda, S. Williamson, W. I Sun, Journal of Clinical Medicine, 8/16/2020
- Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular CarcinomaRobin Park, Fariha Eshrat, Mohammed Al-Jumayli, Azhar Saeed, Anwaar Saeed, Multidisciplinary Digital Publishing Institute, 7/11/2020
- Association of Serrated polyps with extracolonic malignancies.Mohammed AL-Jumayli,MD,D. Goldsmith, J Rogart,MD, The American Journal of Surgical Pathology
- Join now to see all
Abstracts/Posters
- Neoadjuvant cisplatin based therapy in bladder cancer: Is less enough?Saqib Abbasi, Mohammed Al-Jumayli, Hannah Hildebrand, Elizabeth Marie Wulff-Burchfield, Eugene K Lee, John A Taylor, Jeffrey Holzbeierlein, Grace Martin, Rahul Atul Pa..., Journal of Clinical Oncology, Chicago,USA, 6/1/2020
- Clinical Outcomes of different management modalities of Anaplastic Thyroid Cancer: A single Center ExperienceMohammed Al-Jumayli, Hameem Kawsar, Prakash Neupane, International Journal of Radiation Oncology• Biology• Physics, Arizona, USA, 2/24/2020
- Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).Mohammed Al-Jumayli, Hannah Hildebrand, Saqib Abbasi, Anup Kasi, Anwaar Saeed, American Society of Clinical Oncolog GI , JCO, US, 1/27/2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









